PA
FATE icon

Parallel Advisors’s Fate Therapeutics FATE Stock Holding History

Parallel Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-345
Closed -$1.64K – 3407
2023
Q2 		$1.64K Buy
345
+191
+124% +$1.05K ﹤0.01% 2807
2023
Q1 		$878 Sell
154
-321
-68% -$1.94K ﹤0.01% 2986
2022
Q4 		$4.79K Buy
475
+230
+94% +$4.32K ﹤0.01% 2362
2022
Q3 		$5K Buy
245
+59
+32% +$1.71K ﹤0.01% 2289
2022
Q2 		$5K Buy
186
+89
+92% +$2.46K ﹤0.01% 2255
2022
Q1 		$4K Sell
97
-25
-20% -$968 ﹤0.01% 2359
2021
Q4 		$7K Buy
122
+98
+408% +$5.55K ﹤0.01% 2252
2021
Q3 		$1K Buy
24
+8
+50% +$628 ﹤0.01% 2849
2021
Q2 		$1K Sell
16
-16
-50% -$1.29K ﹤0.01% 2723
2021
Q1 		$3K Buy
32
+20
+167% +$1.92K ﹤0.01% 2359
2020
Q4 		$1K Buy
+12
New +$745 ﹤0.01% 2419
2019
Q4 		– Sell
-76
Closed -$1K – 2426
2019
Q3 		$1K Hold
76
– – ﹤0.01% 2267
2019
Q2 		$2K Buy
+76
New +$1.37K ﹤0.01% 2074
2017
Q1 		– Sell
-25,000
Closed -$63K – 2008
2016
Q4 		$63K Buy
+25,000
New +$66.9K 0.01% 515

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's FATE Position: Q3 2023 in Review

Parallel Advisors sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 345 shares — an estimated $1.64K sold.

Parallel Advisors first reported a position in FATE in Q4 2016 and held it in 14 quarters. The position peaked at $63K in Q4 2016. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • Parallel Advisors reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Parallel Advisors sold 345 Fate Therapeutics shares in Q3 2023, an estimated $1.64K.
  • Parallel Advisors first reported a position in Fate Therapeutics in Q4 2016 and held it in 14 quarters.
  • Parallel Advisors's Fate Therapeutics position peaked at $63K in Q4 2016.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Parallel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.